WASHINGTON D.C April 23, 2026 — The White House announced Thursday that Regeneron Pharmaceuticals has agreed to sell its prescription drugs at Most-Favored-Nation (MFN) pricing levels — the lowest prices paid by any developed nation — marking the 17th and final major pharmaceutical manufacturer to join President Donald J. Trump’s landmark initiative to slash U.S. drug costs.
In remarks from the Oval Office, President Trump hailed the agreement as historic.
“This will result in the LARGEST drop in prescription drug prices in the history of the United States,” he said. “With this announcement, 17 of the world’s largest pharmaceutical companies, representing 80% of the branded drug market, have now agreed to sell their drugs to American patients at the lowest prices anywhere in the world.”
The deal completes a year-long push that began with an Executive Order signed by President Trump on May 12, 2025, titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” In July 2025, Trump sent letters to the CEOs of 17 leading drugmakers demanding they align U.S. prices with the lowest international rates. All 17 — including Pfizer, Eli Lilly, Novo Nordisk, Merck, Novartis, Johnson & Johnson, AbbVie, and now Regeneron — have now signed on, covering 86% of the branded drug market according to White House figures.
Key benefits of the Regeneron agreement include:
- Medicaid savings: Every state Medicaid program will gain access to MFN prices on new Regeneron products, delivering hundreds of millions of dollars in savings for the most vulnerable Americans.
- Dramatic price cut on Praluent: The company’s powerful cholesterol-lowering drug will drop from $537 to $225 when purchased directly through the TrumpRx platform.
- Free groundbreaking treatment: Regeneron’s new gene therapy Otarmeni — approved today for a rare form of genetic deafness — will be provided at no cost to American families.
- Future innovation: All new Regeneron medicines will be offered at MFN prices to U.S. patients.
- Investment in America: Regeneron pledged $27 billion in U.S. research, development, and manufacturing by 2029, more than doubling its domestic biologic production capacity. This brings total pharmaceutical investments secured under the Trump administration to $448 billion in just 15 months.
The White House stated the agreements “ensure foreign nations can no longer use price controls to freeride on American innovation” while requiring companies to repatriate increased foreign revenue for the benefit of U.S. patients.
President Trump has repeatedly framed the MFN policy as ending decades of Americans subsidizing lower drug prices abroad.
“It’s simple: President Trump refuses to let America get ripped off in the global drug market,” the White House said in its announcement. “The United States will have the LOWEST drug prices anywhere in the world.”
The deals also tie into broader administration efforts, including tariff relief for companies that commit to domestic manufacturing and the launch of TrumpRx.gov, which allows patients to access discounted medicines at MFN-level prices.
This announcement comes as the Trump administration continues to prioritize health care affordability, with officials calling it a major victory for American patients and taxpayers.
About The Author
